(1) In connection with the acquisition of Pathline, the Company recognized $4.8 million of goodwill, reflecting the preliminary allocation of the purchase price to the identifiable assets acquired and liabilities assumed. Please refer to Note 3. Acquisitions and Disposals for further information about the acquisition of Pathline.

(2) In connection with the classification of the disposal group as held for sale, the Company recognized an impairment charge of $3.5 million to write down the carrying value of the group to its estimated fair value less costs to sell. Please refer to Note 3. Acquisitions and Disposals for further information about the planned disposal of Trapelo.

Intangible assets consisted of the following (in thousands):


		June 30, 2025
	Amortization Period (years)	Cost		Accumulated Amortization		Net


Customer Relationships	7 - 15	$	144,301	$	80,410	$	63,891
Developed Technology(1)	10 - 15	276,825		74,487		202,338

Trademarks(2)	15	30,261		8,142		22,119

Trademark - Indefinite lived	—	13,447		—		13,447
Total		$	464,834	$	163,039	$	301,795

(1) Includes an impairment loss of $10.5 million on InVisionFirst®-Lung developed technology and an impairment loss of $4.7 million related to the classification of the disposal group as held for sale. Please refer to Note 3. Acquisitions and Disposals for further information about the planned disposal of Trapelo.


		December 31, 2024
	Amortization Period (years)	Cost		Accumulated Amortization		Net
Customer Relationships	7 - 15	$	143,101	$	75,423	$	67,678
Developed Technology	10 - 15	310,226		75,758		234,468
Marketing Assets	4	549		514		35
Trademarks	15	31,473		7,420		24,053

Trademark - Indefinite lived	—	13,447		—		13,447
Total		$	498,796	$	159,115	$	339,681

The Company records amortization expense within cost of revenue and general and administrative expense on the Consolidated Statement of Operations. The following table summarizes the amortization expense for the three and six months ended June 30, 2025 and 2024 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
Amortization of intangibles included in cost of revenue	$	4,811	$	4,909	$	9,721	$	9,819
Amortization of intangibles included in general and administrative expenses	3,313		3,452		6,765		6,904
Total amortization of intangibles	$	8,124	$	8,361	$	16,486	$	16,723

In the second quarter of 2025, Management evaluated the planned launch of a new product and its impact on the current portfolio, principally InVisionFirst®-Lung. Following the evaluation, Management made a decision to implement a wind-down of the InVisionFirst®-Lung portfolio, resulting in the recognition of an impairment and associated inventory write-off. The impairment charge was measured as the excess of the carrying value of the affected assets over their estimated fair value, which was determined based on undiscounted expected future cash flows. During the three and six months ended June 30, 2025, the Company recorded impairment charges of $11.4 million and an inventory write-off of $0.4 million associated with InVisionFirst®-Lung, a legacy diagnostic test. Impairment charges consisted of a $10.5 million loss on developed technology and a $0.9 million loss on trademarks. The impairment charge and inventory write-off are included within impairment charges in the Consolidated Statements of Operations.